Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $217,965 | 56 | 88.5% |
| Travel and Lodging | $19,498 | 18 | 7.9% |
| Unspecified | $4,900 | 4 | 2.0% |
| Food and Beverage | $3,935 | 35 | 1.6% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | $93,518 | 41 | $0 (2024) |
| EMD Serono, Inc. | $88,323 | 35 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $21,585 | 12 | $0 (2024) |
| EMD Serono Research & Development Institute | $20,835 | 11 | $0 (2017) |
| Innocoll Incorporated | $8,000 | 1 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,900 | 4 | $0 (2022) |
| Eli Lilly and Company | $4,500 | 4 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $3,375 | 2 | $0 (2017) |
| Taiho Oncology, Inc. | $1,261 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,245 | 6 | Chugai Pharmaceutical Co., Ltd. ($13,360) |
| 2023 | $43,578 | 14 | Chugai Pharmaceutical Co., Ltd. ($38,868) |
| 2022 | $27,180 | 15 | SANOFI-AVENTIS U.S. LLC ($10,990) |
| 2021 | $43,580 | 9 | EMD Serono, Inc. ($27,000) |
| 2020 | $14,465 | 7 | Chugai Pharmaceutical Co., Ltd. ($6,215) |
| 2019 | $34,469 | 22 | EMD Serono, Inc. ($19,131) |
| 2018 | $36,172 | 18 | EMD Serono, Inc. ($26,179) |
| 2017 | $27,609 | 22 | EMD Serono Research & Development Institute ($20,835) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/06/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $12,920.00 | General |
| 06/06/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $398.09 | General |
| 06/06/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| 04/15/2024 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,960.00 | General |
| 02/15/2024 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $785.00 | General |
| 02/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $3,140.00 | General |
| 11/13/2023 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $4,710.00 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $15,188.69 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $11,400.00 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $665.17 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $316.89 | General |
| 08/10/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,520.00 | General |
| 05/23/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 03/16/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $6,840.00 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $715.61 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $317.21 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $184.32 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $123.82 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $76.00 | General |
| 12/07/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | — | Cash or cash equivalent | $650.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES • Category: ONCOLOGY | ||||||
| 11/11/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES • Category: ONCOLOGY | ||||||
| 09/29/2022 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $2,747.50 | General |
| 07/22/2022 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| 06/23/2022 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,570.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | Takeda Pharmaceuticals U.S.A., Inc. | $4,900 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 24 | $6,960 | $1,608 |
| 2022 | 1 | 12 | 31 | $8,773 | $1,912 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 24 | $6,960 | $1,608 | 23.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 31 | $8,773 | $1,912 | 21.8% |
About Dr. Bruce Chabner, MD
Dr. Bruce Chabner, MD is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467443176.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Chabner, MD has received a total of $246,298 in payments from pharmaceutical and medical device companies, with $19,245 received in 2024. These payments were reported across 113 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($217,965).
As a Medicare-enrolled provider, Chabner has provided services to 24 Medicare beneficiaries, totaling 55 services with total Medicare billing of $3,520. Data is available for 2 years (2022–2023), covering 2 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Boston, MA
- Active Since 11/02/2005
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1467443176
Products in Payments
- Non-Covered Product (Drug) $28,920
- Mavenclad (Biological) $10,007
- XARACOLL (Drug) $8,000
- ICLUSIG (Drug) $6,400
- FORTEO (Drug) $4,500
- Bavencio (Biological) $16.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M